Tofacitinib

Regardless of prior tumor necrosis factor inhibitor failure status, Xeljanz was efficacious in patients with ulcerative colitis, according to a study published in Clinical Gastroenterology and Hepatology.

In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed the current state of JAK inhibitors as a newer development in RA treatment, and her approach towards prescribing them in the face of concerns about side effects.

Amy S. Paller, MD, of Northwestern University Feinberg School of Medicine, discussed recent developments in atopic dermatitis and what’s coming up in the pipeline.

In this video, Sonal Choudhary, MD, assistant professor in the department of dermatology at the University of Pittsburgh, discusses treatments in the pipeline for alopecia areata, including the JAK inhibitor tofacitinib (Xeljanz, Pfizer) and platelet rich plasma.